RecruitingNot ApplicableNCT00588185

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate or Salivary Gland Cancer

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer or Salivary Gland Cancer

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

300 participants

Start Date

Feb 1, 2003

Study Type

INTERVENTIONAL

Conditions

Prostate Cancer

Summary

This study will use PET scans, which is a type of x-ray test that uses a radiotracer, to see whether these scans may be better able to find places in the body where your prostate cancer may have spread.

Eligibility

Sex: MALE

Plain Language Summary

Simplified for easier understanding

This study uses two special types of PET scan (a type of medical imaging that tracks how tissues use energy) to evaluate cancer in the body — one scan tracks sugar use by tumors and the other tracks testosterone receptors, which is particularly useful in prostate cancer. **You may be eligible if...** - You have been diagnosed with cancer (particularly prostate cancer or cancers known to have hormone receptors) - You are scheduled for or would benefit from PET scan imaging as part of your evaluation - You are 18 years of age or older **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have poorly controlled diabetes (which can affect the sugar-based PET scan) - You have significant kidney problems that affect how the imaging agents are cleared - You have allergies to the imaging agents used Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone

Registered patients will undergo PET scanning using either FDHT alone or FDG and FDHT depending on the clinical question being asked. Scans will be performed serially at baseline, week 4, week 12, and every 12 weeks of treatment up to a maximum of 8 FDHT/FDG scan set in a 12 month period (maximum 40 scan sets per lifetime) unless the therapeutic protocol or scientific rationale of the therapeutic drug being applied specifically dictates an alternative schedule. Patients may have blood drawn for the purposes of establishing the pharmacokinetics of FDHT and may also undergo an initial dynamic scan if further pharmacokinetic information is warranted, followed by a standard whole body image. If no further pharmacokinetic information is warranted, then patients will only undergo a standard whole body image.